We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.23 | 0.35% | 65.50 | 19.23 | 69.79 | 66.3507 | 64.63 | 65.50 | 12,382,427 | 05:00:04 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Gilead Sciences Inc. (GILD) Tuesday said it named Andrew Dickinson chief financial officer, effective Nov. 1.
The Foster City, Calif., biopharmaceutical company said Mr. Dickinson succeeds Robin Washington, who earlier this year announced plans to retire.
Mr. Dickinson, who joined Gilead in 2016, currently serves as executive vice president of corporate development and strategy and will retain responsibility for those functions, the company said.
Gilead in April said Ms. Washington would remain in an advisory capacity through the completion of the company's reporting of its 2019 financial results early next year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 15, 2019 08:56 ET (12:56 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
